Hub : Traits :

Smoking status: Current

43 significantly associated models · 27 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	43476957	45088053	1	1	1.5e-07	5.8e-11	2.7e-05	59	ST3GAL3
2	3	84767271	86367480	1	1	6.1e-08	5.0e-06	3.9e-03	60	CADM2
3	8	27099879	27720371	2	2	1.0e-09	5.1e-10	4.6e-02	90	CLU EPHX2
4	9	126927285	129422783	8	2	8.5e-10	4.5e-08	7.8e-01	100	MAPKAP1 PRPS1P2
5	9	135521303	136922700	1	1	1.6e-07	2.4e-19	1.5e-15	21	SURF1
6	10	103550604	105647095	6	2	5.2e-09	3.6e-08	6.0e-02	88	ACTR1A NT5C2
7	11	16709350	18106069	1	1	2.2e-07	3.8e-07	4.9e-02	85	KCNJ11
8	15	46780520	48764942	1	1	8.9e-08	1.4e-08	3.4e-03	73	SEMA6D
9	17	78843139	79380547	1	1	1.5e-07	4.2e-07	1.0e+00	100	AATK
10	22	41604557	42180584	4	1	5.2e-08	1.9e-07	1.1e-01	91	PHF5A
11	22	42255525	43674249	1	1	1.3e-07	1.3e-05	8.0e-01	100	RRP7B

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder or Schizophrenia	2.76	3	2	4.4	0.00	1.0e+00	ACTR1A KCNJ11 ST3GAL3
Depressed Affect (Nagel 2018)	1.99	2	1	2.2	0.00	1.0e+00	AATK PHF5A
Depression (Nagel 2018)	2.31	1	0	0.0	0.00	1.0e+00	AATK
Intelligence (Savage-Jansen 2018)	2.49	3	1	2.2	0.00	1.0e+00	AATK ACTR1A ST3GAL3
Neuroticism (Nagel 2018)	3.50	3	1	2.2	0.00	1.0e+00	AATK PHF5A PRPS1P2
Schizophrenia (2018)	3.53	4	1	2.2	0.37	6.3e-01	ACTR1A CLU EPHX2 ST3GAL3
Schizophrenia vs Biploar Disorder	1.78	1	0	0.0	0.00	1.0e+00	CLU
Worry (Nagel 2018)	4.49	5	2	4.4	-0.33	5.9e-01	AATK ACTR1A CADM2 NT5C2 PRPS1P2
Alzheimer’s Disease (in mother)	2.26	1	0	0.0	0.00	1.0e+00	CLU
Alzheimer’s Disease (including proxy)	2.44	2	0	0.0	0.00	1.0e+00	CLU EPHX2
Crohns Disease (2017)	1.33	2	0	0.0	0.00	1.0e+00	NT5C2 PHF5A
Irritable Bowel Disease (IBD)	1.24	1	0	0.0	0.00	1.0e+00	KCNJ11
Ulcerative Colitis (UC)	1.28	1	0	0.0	0.00	1.0e+00	KCNJ11
Verbal and Numeric Reasoning (VNR)	1.97	2	0	0.0	0.00	1.0e+00	ACTR1A ST3GAL3
Breast Cancer	1.12	1	0	0.0	0.00	1.0e+00	CLU
Neuroticism (2016)	2.35	1	0	0.0	0.00	1.0e+00	AATK
Schizophrenia (2014)	3.58	5	1	2.2	0.52	3.6e-01	ACTR1A CLU EPHX2 KCNJ11 ST3GAL3
Ulcerative Colitis	1.20	1	0	0.0	0.00	1.0e+00	KCNJ11
Blood Eosinophil Count	1.47	4	1	2.2	0.08	9.2e-01	AATK KCNJ11 PHF5A SURF1
Blood Platelet Count	0.92	5	3	6.7	0.70	1.9e-01	KCNJ11 NT5C2 PHF5A RRP7B ST3GAL3
Blood Red Count	0.66	3	1	2.2	0.00	1.0e+00	MAPKAP1 ST3GAL3 SURF1
Blood White Count	1.54	6	3	6.7	0.99	2.8e-04	AATK ACTR1A EPHX2 NT5C2 SEMA6D SURF1
Heel T-Score	0.70	2	0	0.0	0.00	1.0e+00	ACTR1A PHF5A
BMI	1.17	3	0	0.0	0.00	1.0e+00	ACTR1A MAPKAP1 RRP7B
Height	1.27	11	4	8.9	-0.47	1.4e-01	AATK ACTR1A CLU KCNJ11 MAPKAP1 NT5C2 PHF5A PRPS1P2 RRP7B ST3GAL3 SURF1
Waist Hip Ratio (WHR)	1.63	3	0	0.0	0.00	1.0e+00	MAPKAP1 PRPS1P2 SEMA6D
Systolic Blood Pressure	2.45	5	2	4.4	-0.94	1.6e-02	ACTR1A CADM2 KCNJ11 MAPKAP1 ST3GAL3
Smoking Status	21.77	14	12	26.7	0.98	2.5e-09	AATK ACTR1A CADM2 CLU EPHX2 KCNJ11 MAPKAP1 NT5C2 PHF5A PRPS1P2 RRP7B SEMA6D ST3GAL3 SURF1
Allergy or Eczema	1.79	2	1	2.2	0.00	1.0e+00	NT5C2 PHF5A
Cardiovascular Disease	1.31	2	0	0.0	0.00	1.0e+00	KCNJ11 MAPKAP1
Hypothyroidism (self reported)	1.19	2	0	0.0	0.00	1.0e+00	KCNJ11 PHF5A
Respiratory disease	2.01	1	1	2.2	0.00	1.0e+00	PHF5A
Type 2 Diabetes (T2D) (2018)	1.55	1	0	0.0	0.00	1.0e+00	KCNJ11
Lung FEV1/FVC ratio	0.89	1	1	2.2	0.00	1.0e+00	ACTR1A
Lung FVC	0.69	2	0	0.0	0.00	1.0e+00	PHF5A PRPS1P2
Neuroticism	3.35	4	1	2.2	-0.05	9.5e-01	AATK ACTR1A PHF5A PRPS1P2
Chronotype (morning person)	1.25	2	0	0.0	0.00	1.0e+00	PHF5A ST3GAL3
Hair Pigment	0.09	1	0	0.0	0.00	1.0e+00	PHF5A
Tanning	0.51	2	1	2.2	0.00	1.0e+00	CADM2 MAPKAP1
Hand grip strength (left)	4.15	5	2	4.4	0.27	6.6e-01	ACTR1A CADM2 MAPKAP1 NT5C2 PRPS1P2
Sensitivity / hurt feelings	3.15	3	0	0.0	0.00	1.0e+00	AATK MAPKAP1 PRPS1P2
Frequency of depressed mood in last 2 weeks	1.98	1	0	0.0	0.00	1.0e+00	AATK
Systolic blood pressure, automated reading	1.84	2	0	0.0	0.00	1.0e+00	KCNJ11 MAPKAP1
Medication for hormone replacement therapy	1.43	1	0	0.0	0.00	1.0e+00	ST3GAL3
Vitamin and mineral supplements	2.58	2	0	0.0	0.00	1.0e+00	ACTR1A NT5C2
Pack years adult smoking proportion	4.81	4	0	0.0	0.99	5.6e-03	MAPKAP1 PRPS1P2 SEMA6D SURF1
Impedance of leg (right)	1.55	4	1	2.2	0.33	6.7e-01	ACTR1A KCNJ11 PRPS1P2 SEMA6D
Leg fat-free mass (left)	1.49	4	1	2.2	0.09	9.1e-01	ACTR1A CADM2 PRPS1P2 SEMA6D
Trunk fat percentage	1.29	2	1	2.2	0.00	1.0e+00	PHF5A SEMA6D
Hand grip strength (right)	3.85	5	2	4.4	0.17	7.8e-01	ACTR1A CADM2 MAPKAP1 NT5C2 PRPS1P2
Townsend deprivation index at recruitment	4.02	4	0	0.0	1.00	1.1e-03	ACTR1A MAPKAP1 PRPS1P2 ST3GAL3
Current tobacco smoking	17.97	14	9	20.0	1.00	7.0e-16	AATK ACTR1A CADM2 CLU EPHX2 KCNJ11 MAPKAP1 NT5C2 PHF5A PRPS1P2 RRP7B SEMA6D ST3GAL3 SURF1
Maternal smoking around birth	7.13	6	1	2.2	0.98	6.2e-04	ACTR1A EPHX2 NT5C2 PHF5A ST3GAL3 SURF1
Fed-up feelings	1.61	2	0	0.0	0.00	1.0e+00	AATK PHF5A
Frequency of unenthusiasm / disinterest in last 2 weeks	2.96	2	0	0.0	0.00	1.0e+00	AATK ST3GAL3
Relative age voice broke	1.87	1	0	0.0	0.00	1.0e+00	RRP7B
Age when periods started (menarche)	2.68	2	1	2.2	0.00	1.0e+00	PRPS1P2 ST3GAL3
High blood pressure	1.31	2	0	0.0	0.00	1.0e+00	KCNJ11 MAPKAP1
Hayfever, allergic rhinitis or eczema	1.77	2	1	2.2	0.00	1.0e+00	NT5C2 PHF5A
Sitting height	1.39	7	0	0.0	-0.78	4.0e-02	AATK KCNJ11 MAPKAP1 PRPS1P2 RRP7B ST3GAL3 SURF1
Body mass index (BMI)	1.43	3	0	0.0	0.00	1.0e+00	ACTR1A CADM2 SEMA6D
Impedance of leg (left)	1.59	4	1	2.2	0.35	6.5e-01	ACTR1A KCNJ11 PRPS1P2 SEMA6D
Leg predicted mass (left)	1.49	4	1	2.2	0.09	9.1e-01	ACTR1A CADM2 PRPS1P2 SEMA6D
Trunk fat mass	1.20	2	0	0.0	0.00	1.0e+00	PHF5A SEMA6D
Waist circumference	1.15	2	0	0.0	0.00	1.0e+00	MAPKAP1 NT5C2
Number of incorrect matches in round	1.28	1	0	0.0	0.00	1.0e+00	NT5C2
Past tobacco smoking	10.09	8	4	8.9	-0.97	7.3e-05	ACTR1A CADM2 CLU EPHX2 MAPKAP1 NT5C2 PRPS1P2 ST3GAL3
Alcohol usually taken with meals	5.64	6	0	0.0	-0.99	1.8e-04	ACTR1A CADM2 CLU EPHX2 NT5C2 SEMA6D
Nervous feelings	4.23	4	1	2.2	-0.44	5.6e-01	AATK ACTR1A CADM2 PRPS1P2
Frequency of tenseness / restlessness in last 2 weeks	2.38	1	0	0.0	0.00	1.0e+00	AATK
Forced vital capacity (FVC)	1.37	2	1	2.2	0.00	1.0e+00	NT5C2 PRPS1P2
Qualifications: None of the above	4.66	3	1	2.2	0.00	1.0e+00	ACTR1A SEMA6D ST3GAL3
Mouth/teeth dental problems	4.46	3	0	0.0	0.00	1.0e+00	AATK EPHX2 PRPS1P2
Allergy	2.11	1	1	2.2	0.00	1.0e+00	PHF5A
Diabetes (self-reported)	1.31	1	0	0.0	0.00	1.0e+00	KCNJ11
Fluid intelligence score	2.81	3	1	2.2	0.00	1.0e+00	AATK KCNJ11 ST3GAL3
Neuroticism score	2.93	3	1	2.2	0.00	1.0e+00	AATK PHF5A PRPS1P2
Weight	1.23	4	1	2.2	0.60	4.0e-01	ACTR1A CADM2 NT5C2 PHF5A
Impedance of arm (right)	2.31	5	3	6.7	-0.99	2.1e-03	ACTR1A CADM2 KCNJ11 NT5C2 PHF5A
Arm fat percentage (right)	1.46	3	0	0.0	0.00	1.0e+00	MAPKAP1 PHF5A SEMA6D
Trunk fat-free mass	1.70	5	2	4.4	0.21	7.3e-01	ACTR1A CADM2 MAPKAP1 NT5C2 PRPS1P2
Hip circumference	1.24	2	0	0.0	0.00	1.0e+00	ACTR1A SEMA6D
Alcohol intake versus 10 years previously	4.55	3	2	4.4	0.00	1.0e+00	CLU EPHX2 NT5C2
Father's age at death	2.26	1	0	0.0	0.00	1.0e+00	CLU
Worrier / anxious feelings	5.06	4	1	2.2	-0.99	9.8e-03	ACTR1A CADM2 NT5C2 PHF5A
Frequency of tiredness / lethargy in last 2 weeks	2.76	3	0	0.0	0.00	1.0e+00	AATK PHF5A PRPS1P2
Number of live births	1.58	1	0	0.0	0.00	1.0e+00	CADM2
Forced expiratory volume in 1-second (FEV1)	2.11	3	1	2.2	0.00	1.0e+00	ACTR1A EPHX2 PRPS1P2
Pulse rate	1.99	1	0	0.0	0.00	1.0e+00	MAPKAP1
Qualifications: A levels/AS levels or equivalent	4.40	4	1	2.2	-0.97	2.7e-02	ACTR1A CADM2 SEMA6D ST3GAL3
Mouth/teeth dental problems: Dentures	4.82	3	0	0.0	0.00	1.0e+00	CLU EPHX2 KCNJ11
Asthma	1.52	1	1	2.2	0.00	1.0e+00	PHF5A
Lung cancer (father)	3.70	2	0	0.0	0.00	1.0e+00	CLU RRP7B
Forced expiratory volume in 1-second (FEV1), Best measure	1.60	2	0	0.0	0.00	1.0e+00	EPHX2 PRPS1P2
Impedance of arm (left)	2.40	4	2	4.4	-0.99	1.2e-02	ACTR1A CADM2 KCNJ11 PHF5A
Arm fat mass (right)	1.29	4	0	0.0	-0.03	9.7e-01	ACTR1A CADM2 PHF5A SEMA6D
Trunk predicted mass	1.72	5	2	4.4	0.21	7.4e-01	ACTR1A CADM2 MAPKAP1 NT5C2 PRPS1P2
Standing height	1.33	6	2	4.4	-0.97	1.2e-03	AATK KCNJ11 MAPKAP1 PHF5A PRPS1P2 RRP7B
Tense / 'highly strung'	2.77	2	0	0.0	0.00	1.0e+00	AATK PHF5A
Seen doctor (GP) for nerves, anxiety, tension or depression	2.73	3	0	0.0	0.00	1.0e+00	AATK CADM2 PRPS1P2
Peak expiratory flow (PEF)	2.88	3	1	2.2	0.00	1.0e+00	ACTR1A EPHX2 PRPS1P2
Pulse wave reflection index	1.96	1	0	0.0	0.00	1.0e+00	MAPKAP1
Medication for cholesterol, blood pressure or diabetes	1.01	1	0	0.0	0.00	1.0e+00	MAPKAP1
Gout (self-reported)	1.17	1	0	0.0	0.00	1.0e+00	CADM2
Medication: Amlodipine	1.29	1	0	0.0	0.00	1.0e+00	MAPKAP1
Medication: Ventolin 100micrograms inhaler	1.77	1	0	0.0	0.00	1.0e+00	PHF5A
Forced vital capacity (FVC), Best measure	1.01	1	0	0.0	0.00	1.0e+00	PRPS1P2
Body fat percentage	1.36	3	0	0.0	0.00	1.0e+00	MAPKAP1 PHF5A SEMA6D
Leg fat percentage (right)	1.45	2	0	0.0	0.00	1.0e+00	CADM2 MAPKAP1
Arm fat-free mass (right)	1.74	4	1	2.2	0.57	4.3e-01	ACTR1A CADM2 NT5C2 PRPS1P2
Exposure to tobacco smoke outside home	3.89	1	0	0.0	0.00	1.0e+00	ACTR1A
Comparative body size at age 10	2.37	2	1	2.2	0.00	1.0e+00	CADM2 PHF5A
Worry too long after embarrassment	2.49	1	0	0.0	0.00	1.0e+00	PRPS1P2
Seen a psychiatrist for nerves, anxiety, tension or depression	2.14	1	0	0.0	0.00	1.0e+00	PRPS1P2
Number of children fathered	1.47	1	0	0.0	0.00	1.0e+00	CADM2
Qualifications: College or University degree	5.42	7	4	8.9	-0.94	1.6e-03	ACTR1A CADM2 NT5C2 PRPS1P2 RRP7B SEMA6D ST3GAL3
Medication for pain relief, constipation, heartburn	0.93	1	0	0.0	0.00	1.0e+00	PRPS1P2
Medication: Blood pressure	0.95	1	0	0.0	0.00	1.0e+00	MAPKAP1
Migraine (self-reported)	2.04	1	0	0.0	0.00	1.0e+00	RRP7B
Whole body fat mass	1.32	4	0	0.0	-0.03	9.7e-01	ACTR1A CADM2 PHF5A SEMA6D
Leg fat mass (right)	1.58	2	0	0.0	0.00	1.0e+00	ACTR1A CADM2
Arm predicted mass (right)	1.74	4	1	2.2	0.56	4.4e-01	ACTR1A CADM2 NT5C2 PRPS1P2
Pulse rate, automated reading	3.07	1	1	2.2	0.00	1.0e+00	MAPKAP1
Alcohol intake frequency.	1.87	2	0	0.0	0.00	1.0e+00	PHF5A RRP7B
Comparative height size at age 10	1.63	3	1	2.2	0.00	1.0e+00	KCNJ11 MAPKAP1 ST3GAL3
Number of full sisters	1.87	1	0	0.0	0.00	1.0e+00	CADM2
Suffer from 'nerves'	2.82	2	0	0.0	0.00	1.0e+00	AATK ACTR1A
Overall health rating	3.08	3	0	0.0	0.00	1.0e+00	AATK MAPKAP1 PRPS1P2
Chest pain or discomfort	1.93	1	0	0.0	0.00	1.0e+00	AATK
Qualifications: NVQ or HND or HNC or equivalent	2.29	1	0	0.0	0.00	1.0e+00	ACTR1A
Knee pain experienced in last month	1.96	1	0	0.0	0.00	1.0e+00	ACTR1A
Hypertension (Self-reported)	1.35	2	0	0.0	0.00	1.0e+00	KCNJ11 MAPKAP1
Smoking status: Previous	5.50	4	0	0.0	1.00	4.2e-04	ACTR1A CADM2 EPHX2 NT5C2
Whole body fat-free mass	1.61	4	2	4.4	0.47	5.3e-01	ACTR1A CADM2 NT5C2 PRPS1P2
Leg fat-free mass (right)	1.41	3	1	2.2	0.00	1.0e+00	ACTR1A PRPS1P2 SEMA6D
Arm fat percentage (left)	1.54	4	0	0.0	-0.42	5.8e-01	MAPKAP1 PHF5A RRP7B SEMA6D
Handedness (chirality/laterality): Left-handed	1.44	1	0	0.0	0.00	1.0e+00	SEMA6D
Mood swings	1.99	1	0	0.0	0.00	1.0e+00	PHF5A
Long-standing illness, disability or infirmity	2.17	1	0	0.0	0.00	1.0e+00	CLU
Ever had bowel cancer screening	2.08	1	0	0.0	0.00	1.0e+00	SURF1
Diabetes diagnosed by doctor	1.41	1	0	0.0	0.00	1.0e+00	KCNJ11
Qualifications: nursing, teaching	3.62	2	1	2.2	0.00	1.0e+00	ACTR1A CADM2
Medication: Laxatives (e.g. Dulcolax, Senokot)	1.99	1	0	0.0	0.00	1.0e+00	MAPKAP1
Back pain experienced in last month	2.45	1	0	0.0	0.00	1.0e+00	AATK
Mineral and other dietary supplements	1.85	2	0	0.0	0.00	1.0e+00	ACTR1A NT5C2
Asthma (self-reported)	1.62	1	1	2.2	0.00	1.0e+00	PHF5A
Osteoarthritis (self-reported)	2.38	1	0	0.0	0.00	1.0e+00	MAPKAP1
Medication: Gliclazide	1.34	1	0	0.0	0.00	1.0e+00	KCNJ11
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.36	2	0	0.0	0.00	1.0e+00	EPHX2 PRPS1P2
Whole body water mass	1.61	4	2	4.4	0.46	5.4e-01	ACTR1A CADM2 NT5C2 PRPS1P2
Leg predicted mass (right)	1.40	3	1	2.2	0.00	1.0e+00	ACTR1A PRPS1P2 SEMA6D
Arm fat mass (left)	1.39	4	0	0.0	-0.01	9.9e-01	ACTR1A CADM2 PHF5A SEMA6D
Number of self-reported non-cancer illnesses	1.60	1	0	0.0	0.00	1.0e+00	PHF5A
Miserableness	1.25	1	0	0.0	0.00	1.0e+00	AATK
Guilty feelings	2.46	1	0	0.0	0.00	1.0e+00	AATK
Wears glasses or contact lenses	1.84	1	0	0.0	0.00	1.0e+00	CADM2
Mother's age at death	3.60	2	0	0.0	0.00	1.0e+00	CADM2 MAPKAP1
Financial situation satisfaction	3.24	2	0	0.0	0.00	1.0e+00	CADM2 KCNJ11
Commuting to job workplace: Public transport	1.94	1	0	0.0	0.00	1.0e+00	CADM2
Medication: Blood pressure	1.00	1	0	0.0	0.00	1.0e+00	KCNJ11
High cholesterol (Self-reported)	0.98	1	0	0.0	0.00	1.0e+00	SURF1
Ever smoked	8.55	6	4	8.9	1.00	3.1e-05	AATK ACTR1A CADM2 KCNJ11 NT5C2 PRPS1P2
Basal metabolic rate	1.48	4	1	2.2	0.50	5.0e-01	ACTR1A CADM2 NT5C2 PRPS1P2
Leg fat percentage (left)	1.41	1	0	0.0	0.00	1.0e+00	MAPKAP1
Arm fat-free mass (left)	1.69	4	1	2.2	0.57	4.3e-01	ACTR1A CADM2 NT5C2 PRPS1P2
Average weekly beer plus cider intake	2.09	1	0	0.0	0.00	1.0e+00	CADM2
Irritability	2.65	1	0	0.0	0.00	1.0e+00	PHF5A
Risk taking	4.87	2	1	2.2	0.00	1.0e+00	CADM2 NT5C2
Age started oral contraceptive pill	2.18	1	0	0.0	0.00	1.0e+00	CADM2
Diastolic blood pressure, automated reading	1.73	3	0	0.0	0.00	1.0e+00	MAPKAP1 NT5C2 ST3GAL3
Vascular/heart problems diagnosed by doctor	1.18	2	0	0.0	0.00	1.0e+00	MAPKAP1 NT5C2
Cholesterol lowering medication	1.25	1	0	0.0	0.00	1.0e+00	SURF1
Medication: Omeprazole (e.g. Zanprol)	1.81	1	0	0.0	0.00	1.0e+00	KCNJ11
Pain experienced in last month	1.67	1	0	0.0	0.00	1.0e+00	PRPS1P2
Basal cell carcinoma (self-reported)	0.96	1	0	0.0	0.00	1.0e+00	PHF5A
Pack years of smoking	4.47	2	0	0.0	0.00	1.0e+00	SEMA6D SURF1
Impedance of whole body	2.17	5	2	4.4	-0.55	3.3e-01	ACTR1A CADM2 KCNJ11 PHF5A PRPS1P2
Leg fat mass (left)	1.50	2	0	0.0	0.00	1.0e+00	ACTR1A CADM2
Arm predicted mass (left)	1.63	4	1	2.2	0.54	4.6e-01	ACTR1A CADM2 NT5C2 PRPS1P2

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	1	0.029	1.7
GTEx	Adipose Visceral Omentum	1	0.049	1.6
GTEx	Adrenal Gland	0	0.000	1.7
GTEx	Artery Aorta	0	0.000	1.6
GTEx	Artery Coronary	1	0.085	1.6
GTEx	Artery Tibial	2	0.053	1.6
GTEx	Brain Caudate basal ganglia	0	0.000	1.6
GTEx	Brain Cerebellar Hemisphere	1	0.067	1.6
GTEx	Brain Cerebellum	2	0.101	1.6
GTEx	Brain Cortex	2	0.193	1.7
GTEx	Brain Frontal Cortex BA9	0	0.000	1.7
GTEx	Brain Hippocampus	0	0.000	1.5
GTEx	Brain Hypothalamus	0	0.000	1.6
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.6
GTEx	Brain Putamen basal ganglia	0	0.000	1.4
GTEx	Breast Mammary Tissue	0	0.000	1.7
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.6
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.5
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.6
GTEx	Cells Transformed fibroblasts	2	0.048	1.6
GTEx	Colon Sigmoid	0	0.000	1.7
GTEx	Colon Transverse	0	0.000	1.6
GTEx	Esophagus Gastroesophageal Junction	0	0.000	1.7
GTEx	Esophagus Mucosa	0	0.000	1.6
GTEx	Esophagus Muscularis	0	0.000	1.7
GTEx	Heart Atrial Appendage	0	0.000	1.6
GTEx	Heart Left Ventricle	0	0.000	1.7
GTEx	Liver	1	0.139	1.6
GTEx	Lung	0	0.000	1.6
GTEx	Muscle Skeletal	1	0.035	1.7
GTEx	Nerve Tibial	1	0.023	1.6
GTEx	Ovary	0	0.000	1.5
GTEx	Pancreas	0	0.000	1.7
GTEx	Pituitary	0	0.000	1.6
GTEx	Prostate	0	0.000	1.7
GTEx	Skin Not Sun Exposed Suprapubic	1	0.041	1.6
GTEx	Skin Sun Exposed Lower leg	2	0.055	1.6
GTEx	Small Intestine Terminal Ileum	0	0.000	1.6
GTEx	Spleen	1	0.071	1.6
GTEx	Stomach	0	0.000	1.7
GTEx	Testis	0	0.000	1.6
GTEx	Thyroid	1	0.025	1.6
GTEx	Uterus	0	0.000	1.6
GTEx	Vagina	0	0.000	1.5
GTEx	Whole Blood	1	0.050	1.6
METSIM	Adipose	0	0.000	1.5
NTR	Blood	1	0.042	1.5
ROSMAP	Brain Pre-frontal Cortex	2	0.046	1.6
YFS	Blood	0	0.000	1.5
CommonMind	Brain Pre-frontal Cortex	2	0.037	1.6
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	1	0.060	1.6
The Cancer Genome Atlas	Breast Invasive Carcinoma	2	0.045	1.5
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Colon Adenocarcinoma	0	0.000	1.7
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.6
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	1	0.024	1.6
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.098	1.6
The Cancer Genome Atlas	Brain Lower Grade Glioma	2	0.046	1.6
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Lung Adenocarcinoma	0	0.000	1.6
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	2	0.080	1.6
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	0	0.000	1.6
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	0	0.000	1.6
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	1	0.075	1.6
The Cancer Genome Atlas	Prostate Adenocarcinoma	0	0.000	1.5
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.7
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.6
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.6
The Cancer Genome Atlas	Stomach Adenocarcinoma	0	0.000	1.6
The Cancer Genome Atlas	Testicular Germ Cell Tumors	2	0.156	1.6
The Cancer Genome Atlas	Thyroid Carcinoma	2	0.039	1.6
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.7